0001493152-26-009370
SEC filingAnixa Biosciences reported a net loss of $2.6 million for Q1 2026, consistent with its operating loss of $2.7 million, as the company generated no revenue during the period. The loss was driven by research and development expenses of $1.1 million and general and administrative expenses of $1.6 million, totaling $2.7 million in operating costs. Interest income of $131,000 partially offset the operating loss. The company ended the quarter with $15.2 million in total assets, including $1.5 million in cash and cash equivalents and $12.7 million in short-term investments, while maintaining total liabilities of $1.4 million. Cash flow from operations was negative $2.6 million, but investing activities provided $1.2 million and financing activities contributed $1.7 million, resulting in a net increase in cash of $303,000. The company's accumulated deficit grew to $254.2 million, reflecting its ongoing investment in research and development without current revenue generation.
Anixa Biosciences reported a net loss of $2.6 million for the first quarter of fiscal year 2026, ending January 31, 2026. The company generated no revenue during the period, resulting in an operating loss of $2.7 million. Operating expenses totaled $2.7 million, consisting of $1.1 million in research and development expenses and $1.6 million in general and administrative expenses. Interest income of $131,000 partially offset the operating loss. The net loss attributable to common shareholders was $2.6 million, with a $20,000 reduction from noncontrolling interest. The company reported basic and diluted net loss per share of $0, with weighted average common shares outstanding of 33.2 million for both basic and diluted calculations.
No revenue was reported for the quarter ending January 31, 2026. The income statement shows no revenue line items, and the XBRL data confirms revenue was not disclosed. The document content and XBRL financial data sections both indicate no revenue generation during the period. The company's financial performance was entirely driven by operating expenses and interest income, with no segment or geographic revenue breakdown provided in the filing.
With no revenue generated, gross margin and operating margin calculations are not applicable. The company reported an operating loss of $2.7 million, driven by research and development expenses of $1.1 million and general and administrative expenses of $1.6 million. Non-cash stock-based compensation expenses were included in both categories: $338,000 in R&D and $458,000 in G&A. The cost structure shows continued investment in research activities without corresponding revenue, resulting in negative profitability metrics. Interest income of $131,000 provided a partial offset to the operating loss.
Cash flow from operating activities was negative $2.6 million, primarily due to the net loss of $2.6 million, partially offset by non-cash adjustments including $768,000 in stock option compensation and $28,000 in stock options issued to consultants. Investing activities provided $1.2 million in cash, with $13.8 million from maturities of short-term investments offset by $12.5 million in new short-term investment disbursements. Financing activities contributed $1.7 million, including $1.6 million from an at-the-market offering and $60,000 from stock option exercises. The balance sheet shows total assets of $15.2 million, including $1.5 million in cash and cash equivalents and $12.7 million in short-term investments. Total liabilities were $1.4 million, with current liabilities of $1.2 million. Shareholders' equity was $15.1 million, with accumulated deficit of $254.2 million.
The filing does not contain specific forward-looking guidance, management projections, or explicit strategic priorities for future periods. No revenue forecasts, expense projections, or specific risk factors beyond standard contingencies are disclosed in the provided content. The company's financial position shows continued investment in research and development activities without current revenue generation, with liquidity maintained through short-term investments and equity financing activities.